stoxline Quote Chart Rank Option Currency Glossary
  
Rhythm Pharmaceuticals, Inc. (RYTM)
112.36  -4.44 (-3.8%)    11-20 16:00
Open: 115.765
High: 116.7
Volume: 1,502,362
  
Pre. Close: 116.8
Low: 112
Market Cap: 7,790(M)
Technical analysis
2026-11-20 4:47:39 PM
Short term     
Mid term     
Targets 6-month :  141.8 1-year :  165.63
Resists First :  121.41 Second :  141.8
Pivot price 109.67
Supports First :  96.79 Second :  81.57
MAs MA(5) :  114.45 MA(20) :  105.21
MA(100) :  103.47 MA(250) :  99.3
MACD MACD :  5.7 Signal :  4.8
%K %D K(14,3) :  86.5 D(3) :  88.6
RSI RSI(14): 57.2
52-week High :  122.19 Low :  74.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RYTM ] has closed below upper band by 42.2%. Bollinger Bands are 98.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 116.75 - 117.54 117.54 - 118.19
Low: 110.52 - 111.27 111.27 - 111.9
Close: 111.26 - 112.48 112.48 - 113.49
Company Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

Headline News

Wed, 18 Nov 2026
Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out (RYTM) - Seeking Alpha

Wed, 18 Nov 2026
Rhythm Pharmaceuticals Stock Price Forecast. Should You Buy RYTM? - StockInvest.us

Tue, 17 Nov 2026
Rhythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR (RYTM:NASDAQ) - Seeking Alpha

Tue, 17 Nov 2026
Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions - Benzinga

Wed, 11 Nov 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Seasonal returns chart - Yahoo Finance - Yahoo Finance Singapore

Fri, 06 Nov 2026
Rhythm Pharmaceuticals gains on report of additional bidder (RYTM:NASDAQ) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 69 (M)
Shares Float 57 (M)
Held by Insiders 0.6 (%)
Held by Institutions 114.5 (%)
Shares Short 11,000 (K)
Shares Short P.Month 10,290 (K)
Stock Financials
EPS -2.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.26
Profit Margin -69.1 %
Operating Margin -42.7 %
Return on Assets (ttm) -24.7 %
Return on Equity (ttm) -78 %
Qtrly Rev. Growth 79.5 %
Gross Profit (p.s.) 3.57
Sales Per Share 4.04
EBITDA (p.s.) -2.69
Qtrly Earnings Growth 0 %
Operating Cash Flow -82 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -38.62
PEG Ratio 0
Price to Book value 88.47
Price to Sales 27.74
Price to Cash Flow -95.25
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android